?Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences

November 6, 2019 sandiegobiotech News Comments Off on ?Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences
?Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences
/

SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento?s research team will participate in upcoming industry conferences in the 4th quarter 2019.

Related Articles

No Picture
News

Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)

December 7, 2021 sandiegobiotech News Comments Off on Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)

SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the Phase 2 clinical study of RTX for treating knee pain from osteoarthritis (OA) has begun enrollment. This study is a multi-center, double blind, placebo- and active-controlled study to assess the safety… Click here to view original post… […]

No Picture
News

Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel

August 23, 2021 sandiegobiotech News Comments Off on Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel

SAN DIEGO, Aug. 23, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released a patient case report on the lymphatic delivery of Enbrel using the Sofusa Lymphatic Delivery System (SOFUSA), which has been submitted for preprint as CASE REPORT: Lymphatic delivery of Enbrel® using The Sofusa® Lymphatic… Click here to view original post… […]

No Picture
News

Sorrento Mexico and the National Institute of Genomic Medicine (INMEGEN) of Mexico Government Execute Memorandum of Understanding (MOU) for Rapid Clinical Development of COVID-19 Diagnostics, Therapeutics and Multivalent mRNA-Based Vaccines Against SARS-CoV-2 and Its Variants of Concerns

August 3, 2021 sandiegobiotech News Comments Off on Sorrento Mexico and the National Institute of Genomic Medicine (INMEGEN) of Mexico Government Execute Memorandum of Understanding (MOU) for Rapid Clinical Development of COVID-19 Diagnostics, Therapeutics and Multivalent mRNA-Based Vaccines Against SARS-CoV-2 and Its Variants of Concerns

SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that its subsidiary company, Sorrento Therapeutics Mexico (“Sorrento Mexico”), has entered into an MOU agreement with the National Institute of Genomic Medicine INMEGEN (“Instituto National de Medicine Genomica”) to cooperate in the development,… Click here to view original post… […]